Cryoablation Probe Market By Product Type (Single-Use Probes, Reusable Probes), By Application (Oncology, Cardiology, Dermatology, Gynecology, Pain Management, Others), By Technology (Argon-based Cryoablation, Nitrogen-based Cryoablation, Others), By Procedure Type (Percutaneous, Laparoscopic, Open Surgical), and By End-user (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape the Cryoablation Probe Market in the coming years?

The Cryoablation Probe Market accounted for USD 191.20 Million in 2024 and USD 219.31 Million in 2025 is expected to reach USD 864.34 Million by 2035, growing at a CAGR of around 14.7% between 2025 and 2035. The Cryoablation Probe Market is defined as the category of healthcare equipment that entails cryoablation, which is the least destructive procedure that utilizes extreme cold to ablate aberrant or pathological tissue. The cryoablation probes are used to supply regulated freezing agents such as liquid nitrogen or gas to target tissues at a predetermined amount to form an ice crystal that breaks down cells and causes blood flow to be inhibited. The technique is common in the treatment of tumors in various organs (e.g., liver, kidney, prostate, and lungs) in oncology practice, and atrial fibrillation in cardiology by ablating erroneous electrical pathways to the heart to treat the disease.

Increase in the incidence of cancer, an increase in age, and an increase in demand for less invasive options of treatment options that provide faster recovery and cause fewer problems, fosters the market. Advances in technology allowed more accurate, visually guided and adaptable cryoprobes, which makes the procedures more precise and safer. There also is the growth in intake of outpatient and ambulatory care, which is promoting adoption because of the short hospital stays and cost-effectiveness.

What do industry experts say about the Cryoablation Probe market trends?

“Cryoablation has emerged as a critical tool in interventional oncology and electrophysiology, offering precise, minimally invasive treatment with fewer complications and faster recovery times. With ongoing innovation in probe design and real-time imaging integration, we are witnessing a significant shift toward outpatient procedures and personalized care.”

• Dr. Emily Harper, MD, Interventional Radiologist & Associate Professor, Department of Radiology, Johns Hopkins University School of Medicine

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Cryoablation Probe market?

Is the increasing demand for minimally invasive procedures driving the adoption of cryoablation probes?

The growing need for less invasive procedures is one of the primary reasons behind the Cryoablation Probe Market. Healthcare providers and patients are turning more often toward treatments that ensure shorter stays in the hospital, fewer complications, and accelerated recovery processes, and cryoablation can bring all of those. The cryoablation technique, compared to the use of traditional surgical technologies, is ideal to use in both cardiac and cancer therapies because the body tissue used is obliterated under focused cold energy, and small wounds heal after a reasonable procedure. This clinical preference change is backed up by technological changes in imaging and control of the probe, which further allow high degrees of precision in these procedures.

The Centers for Medicare & Medicaid Services (CMS) reports that the number of outpatient surgeries in the U.S. has increased enormously over time, and currently, over 60 percent of all surgeries in this country take place on an outpatient basis. This is as a result of the increased desire to use less invasive procedures, such as cryoablation, which enables faster discharge. Due to the current trend of healthcare systems to lessen their expenses and achieve better patient outcomes, the use of cryoablation probes will continue to increase in the future, particularly in the fields of oncology and interventional cardiology.

How does the rising global prevalence of cancer influence the growth of the cryoablation probe market?

The global surge in cancer rates plays a significant role in the expansion of the cryoablation probe market, as the disease results in the growth of the demand for options of effective and less invasive treatment. Cryoablation finds its place in the treatment of solid tumors of the kidney, liver, breast, and lungs, particularly where resection is not feasible. This is a method of selective destruction of the tumor with minimal effect on healthy tissue around it, a short recovery period, and therefore fewer complications. With the advancement of cancer detection and the escalating number of aging people, a larger number of patients with cancer are being diagnosed early, and therefore represent good candidates for cryoablation therapy.

The technology is also gaining preference in repeat surgeries, as well as for those who cannot be operated on using conventional surgery. The World Health Organization (WHO) asserts that cancer is a major killer throughout the world, and recorded about 10 million people died in 2020, and going forward, more people are likely to succumb to the disease in the coming decades. The sheer increase in cancer rates directly leads to the growing use of cryoablation, enabling it to maintain significant presence in the current treatment plans of the sphere of oncology.

Are high costs associated with cryoablation devices limiting their adoption in low-income regions?

High costs of cryoablation devices provide a major inhibitor in the cryoablation probe market, especially in low-income and resource-limited areas. The cost of the equipment, maintenance, and training of cryoablation systems, as well as disposable probes or single-use probes, is not feasible in a small hospital or clinic, which limits the accessibility of this procedure to them. A large number of developing nations have low healthcare budgets that are usually focused on the simplest forms of treatment and the handling of infectious diseases, with little incentive to carry out more advanced procedures that require significant investment.

There is also no reimbursement coverage in such fields, which adds to the deterrence of adoption since patients are expected to meet the entire cost of treatment. Also, it increases the overall cost because there is an infrastructure, like CT or MRI, required to administer image-guided cryoablation. Consequently, the cost of the upfront and procedure is still a huge deterrent to its widespread application to impede market penetration in low-income markets.

Can expanding applications in breast and soft tissue tumor treatment open new market avenues?

The cryoablation probe market is demonstrating a major prospect with escalating usage in breast and soft tissue tumor therapy. Cryoablation is becoming popular in the treatment of early-stages cancers in the breast and benign breast tumor including fibroadenomas but with a high degree of patient satisfaction with less scarring and faster healing process. The possibility of its being used to treat soft tissue tumor in the lungs, kidney, and liver further expounds its clinical application.

Such applications are of great importance to the patients who cannot undergo surgery because of their age or comorbidity. Clinical trials offer the promise that regulatory approvals will soon follow, so as cryoablation demonstrates its safety and effectiveness as a treatment alternative in these domains, new markets will be opened. Adoption is also being spurred by the increasing awareness on the part of oncologists and patients alike, regarding these benefits. This transition not only makes the utilization of cryoprobes more diverse, but its dynamics motivate the demand in the developed and emerging healthcare markets as well.

Is rising medical tourism in Asia-Pacific creating opportunities for affordable cryoablation procedures?

Cryoablation Probe Market has the opportunity of its growth with increasing medical tourism in the Asia-Pacific region. Indian, Thailand, and Singapore are some of the places where international patients are hosting the moves because of affordable medical facilities and quality medical infrastructures. Cryoablation, which is a minimally invasive and dose-efficient procedure of treating the cardiac conditions and tumor is another process that complements the current services in the outbound medical tourism.

Such processes are usually cheaper as compared to western countries and therefore are appealing to those patients who want more sophisticated services at lesser prices. Also, the hospitals in the region have been investing on modern technologies such as cryoablation systems in efforts to match the world standards. This trend is further buttressed by the availability of skilled health professional and reduction in the waiting time. With the growth of medical tourism which is becoming more popular each day, more markets are opening up to the uptake and expansion of the Cryoablation Probe Market in Asia-Pacific.

What are the key market segments in the Cryoablation Probe industry?

Based on the product type, the Cryoablation Probe Market is classified into Single-Use Probes, Reusable Probes. Single-Use Probes is the most dominant segment in the Cryoablation Probe Market. This leadership can be attributed to growing concerns about cross-contamination, the growing need to have sterile equipment, and the ease of not having to reprocess surgical instruments after every procedure. Single-use probes specifically are suitable in the field of oncology and cardiology, where accuracy and cleanliness count.

They minimize the possibility of infection, eliminate the need to spend time sterilizing the equipment, and match hospital guidelines to patient safety. In addition, regulatory agencies and healthcare standards are becoming more inclined to disposable medical devices; this trend has also contributed to the use of single-use cryoablation catheters in clinical practice.

Based on the application, the Cryoablation Probe Market is classified into Oncology, Cardiology, Dermatology, Gynecology, Pain Management, and Others. The largest application segment in the cryoablation probe market is oncology. The increased worldwide cases of cancers, especially in the liver, kidney, breast, and lungs, have fueled the demand for minimally invasive treatments of such diseases, such as the cryoablation technique. It is well-suited for the treatment of cancer because this method allows the tumor to be targeted, and minimal harm is done to the healthy tissues around it. It is commonly applied in patients who cannot undergo orthodox surgery owing to age or comorbidities.

Also, there have been improvements in imaging modalities that result in accurate tumor localization during the cryoablation procedure, which augurs well for clinical outcomes. The increasing rates of clinical evidence for the safety and effectiveness of cryotherapy in oncology have also spurred its usage among the healthcare providers. As more people learn and wish to embrace the non-surgical means of treating cancer, the oncology part of the market remains dominant.

Which regions are leading the Cryoablation Probe market, and why?

The North American market is reported to be captured by its high level of chronic cases like cancer and atrial fibrillation, where cryoablation has recently been employed as a minimally invasive option of treatment. As an advantage, the area is well equipped with healthcare infrastructure, favorable reimbursement systems, and a high priority role in the treatment of disease early. The U.S. is the market leader because of the increase in the expenditure on healthcare, regular upgrading of the technology, and availability of specialized care facilities all over.

Canada is continuing to grow steadily with the help of investments into the national healthcare system and the rising awareness among patients about the existence of less invasive treatment options. Increase in demand for shorter stays and outpatient procedures has contributed to the rising demand for cryoablation both within the hospital and outside the hospital. Additionally, North America has taken the lead under the influence of clinical research and regulatory support of the innovative cryotherapy solutions, thereby increasing its position in both market value and volume of procedures.

The Asia-Pacific cryoablation probe industry is showing a flourishing growth pattern with the rising number of cancer cases, high healthcare awareness, and increased availability of superior health technologies. The demand for minimally invasive procedures is soaring in countries such as China, India, Japan, and South Korea on account of increasing urbanization and refined health infrastructure. Other measures to boost the market have been through government efforts in enhancing cancer screening and treatment programs.

Another factor that is influenced heavily is medical tourism, mainly in Southeast Asia, where affordable and quality healthcare is drawing in foreigners. The use of cryoablation is on the increase in oncology and cardiology procedures as hospitals and referral clinics are investing in updated state-of-the-art equipment. Although there are certain regulatory issues and cost factors, the region still has a great long-term potential given the existing population base, rising health spending, as well as continuous work on the modernization of both the public and the privately owned systems of care. 

What does the competitive landscape of the Cryoablation Probe market look like?

The Cryoablation Probe Market is competitive with an amalgamation of international medical equipment conglomerates and dedicated cryotherapy instrument companies. The major competitors in the space include Medtronic plc, Boston Scientific Corporation, and Stryker Corporation, which have opportunities based on a large product portfolio, robust R&D services, and a distribution network. These businesses lie on the convergence of cryoablation with advanced imaging and navigation technologies used to promote procedural accuracy and clinical results.

New entrants such as IceCure Medical Ltd. and HistoSonics Inc. are making a name by bringing out very exciting products in the field of minimally invasive cryotherapy of tumors of the breast, kidney, and the lungs. Product developments and clinical validation are also being executed through collaborations with hospitals, cancer centers, and academic institutions. Moreover, Galil Medical and Endocare Inc. remain on the solid ground of the company's presence on the market and its niche oncology and urology products.

Cryoablation Probe Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Cryoablation Probe industry?

• In April 2024, AtriCure introduced its advanced CryoSphere+ cryoablation probe for the CryoIce platform, featuring improved insulation that reduces freeze times by 25% compared to the earlier CryoSphere model.
• In July 2024, IceCure Medical Ltd. received FDA marketing authorization for its next-generation XSense Cryoablation System with CryoProbes, a single-probe solution designed to non-surgically eliminate tumors through targeted freezing.

Report Coverage:

By Product Type

• Single-Use Probes
• Reusable Probes

By Application

• Oncology
• Cardiology
• Dermatology
• Gynecology
• Pain Management
• Others

By Technology

• Argon-based Cryoablation
• Nitrogen-based Cryoablation
• Others

By Procedure Type

• Percutaneous
• Laparoscopic
• Open Surgical

By End-user

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Medtronic plc
• Boston Scientific Corporation
• Galil Medical
• IceCure Medical Ltd.
• Stryker Corporation
• Johnson & Johnson
• CooperSurgical Inc.
• Terumo Corporation
• Varian Medical Systems
• Zimmer Biomet Holdings Inc.
• BVM Medical Ltd.
• Endocare Inc.
• Erbe Elektromedizin GmbH
• MedWaves Inc.
• HistoSonics Inc.

Frequently Asked Questions (FAQs)